急性膵炎の世界市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、治療別、診断別、エンドユーザー別、地域別、競合

世界の急性膵炎市場は、2022年に51億米ドルと評価され、2028年までのCAGRは5.59％で、予測期間中に力強い成長を予測しています。

世界の急性膵炎市場は、膵臓の重篤な炎症状態である急性膵炎の診断、治療、管理を包括するヘルスケア産業内のダイナミックで進化するセクターです。この市場は、ライフスタイルの変化、アルコール消費量の増加、肥満の罹患率の上昇など様々な要因により、近年著しい成長と変貌を遂げています。

この市場の主な促進要因のひとつは、急性膵炎に対する認識の高まりと早期診断であり、そのため、急性膵炎を正確に特定し重症度を評価するための画像検査や血液検査などの診断検査に対する需要が急増しています。さらに、医療技術の進歩は、急性膵炎の診断と管理の改善に極めて重要な役割を果たしており、内視鏡技術や低侵襲手技の革新は、より効果的な治療選択肢を提供しています。

急性膵炎の治療法も、疼痛管理、栄養補給、膵壊死や感染症などの合併症の予防に重点を置き、大きな進歩を遂げています。製薬業界は、炎症を抑え、痛みを和らげ、膵炎患者のQOL（生活の質）を高めることを目的とした新薬や治療法を開発することで対応しています。

急性膵炎市場は、医薬品と診断薬に加えて、病院での治療、外科的介入、リハビリテーション・プログラムなど幅広いヘルスケア・サービスを包含しており、これらすべてが市場の成長と複雑性に寄与しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別（輸液、栄養補給、鎮痛薬、内視鏡的逆行性胆管膵管造影（ERCP）、その他の治療法）
  • 診断別（画像検査、臨床検査）
  • エンドユーザー別（病院・クリニック、外来医療センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 治療別
  • 診断別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの急性膵炎市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 急性膵炎の世界市場世界の急性膵炎市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• SCM Lifescience
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Acute Pancreatitis Market has valued at USD 5.10 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.59% through 2028. The Global Acute Pancreatitis Market is a dynamic and evolving sector within the healthcare industry that encompasses the diagnosis, treatment, and management of acute pancreatitis, a severe inflammatory condition of the pancreas. This market has witnessed significant growth and transformation in recent years due to various factors, including changing lifestyle patterns, increasing alcohol consumption, and a rising incidence of obesity, all of which are contributing to the growing prevalence of acute pancreatitis worldwide.

One of the key drivers of this market is the increasing awareness and early diagnosis of acute pancreatitis, which has led to a surge in demand for diagnostic tests, such as imaging studies and blood tests, to accurately identify and assess the severity of the condition. Moreover, advancements in medical technology have played a pivotal role in improving the diagnosis and management of acute pancreatitis, with innovations in endoscopic techniques and minimally invasive procedures offering more effective treatment options.

The treatment landscape of acute pancreatitis has also witnessed significant advancements, with a focus on better pain management, nutritional support, and the prevention of complications such as pancreatic necrosis and infection. The pharmaceutical sector has responded by developing novel drugs and therapies that aim to reduce inflammation, alleviate pain, and enhance the overall quality of life for patients suffering from this condition.

In addition to pharmaceuticals and diagnostics, the acute pancreatitis market encompasses a wide range of healthcare services, including hospital care, surgical interventions, and rehabilitation programs, all of which contribute to the market's growth and complexity.

Key Market Drivers

Changing Lifestyle Patterns and Risk Factors

The global acute pancreatitis market is experiencing significant growth, in large part due to changing lifestyle patterns and the associated risk factors that are driving the increasing prevalence of this painful and potentially life-threatening condition. Modern lifestyles characterized by unhealthy dietary habits, high alcohol consumption, and a rising global obesity epidemic have created a perfect storm of risk factors that are contributing to the surge in acute pancreatitis cases worldwide.

One of the key drivers behind this phenomenon is the consumption of alcohol, a well-established risk factor for acute pancreatitis. As societies across the globe embrace more indulgent drinking habits, there has been a marked increase in the number of individuals suffering from alcohol-induced acute pancreatitis. This has led to a greater demand for diagnostic services to accurately identify the condition and initiate timely treatment, thus boosting the market for acute pancreatitis-related healthcare services.

Additionally, the prevalence of obesity is on the rise globally, and obesity is closely linked to the development of acute pancreatitis. Excess body fat and obesity can trigger inflammation of the pancreas, making individuals more susceptible to this condition. With obesity rates continuing to climb, healthcare providers are faced with a growing number of patients at risk for acute pancreatitis, driving the demand for preventive measures, early diagnosis, and effective treatment options.

Furthermore, unhealthy dietary choices, characterized by the consumption of high-fat, high-sugar, and processed foods, play a significant role in the development of acute pancreatitis. These dietary patterns can lead to the formation of gallstones, a common cause of pancreatitis. As people increasingly adopt these dietary habits, the risk of gallstone-related pancreatitis rises, necessitating medical intervention and further bolstering the acute pancreatitis market.

Advancements in Diagnostic Techniques

The global acute pancreatitis market has witnessed significant growth, driven in no small part by remarkable advancements in diagnostic techniques. The ability to accurately and swiftly diagnose acute pancreatitis is crucial for effective management and improved patient outcomes, and recent innovations in this regard have had a profound impact on the market.

One of the key drivers of market growth is the advent of sophisticated imaging studies. Computed Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and ultrasound techniques have all undergone substantial improvements in terms of accuracy and accessibility. These imaging modalities enable healthcare professionals to visualize the pancreas and surrounding structures with greater precision, aiding in early diagnosis and assessment of the severity of acute pancreatitis. As these diagnostic tools become more readily available and affordable, they have become integral in the timely identification of the condition, thereby increasing the overall demand for diagnostic services.

Blood tests have also seen notable advancements. Biomarker research and the development of specialized blood panels have allowed for more accurate and specific detection of acute pancreatitis. These tests provide vital information about the condition, including markers of inflammation and pancreatic enzyme levels. These advancements have not only enhanced diagnostic accuracy but have also expedited the diagnostic process, allowing for prompt initiation of treatment and care.

Furthermore, the integration of Artificial Intelligence (AI) and machine learning algorithms into diagnostic tools has added a new dimension to acute pancreatitis diagnosis. AI can analyze large datasets and medical images with remarkable speed and accuracy, helping healthcare professionals make quicker and more precise diagnoses. This not only improves patient care but also contributes to the market's growth as healthcare providers adopt AI-based diagnostic solutions.The widespread adoption of electronic health records (EHRs) and telemedicine has also played a role in the diagnostic process for acute pancreatitis.

Global Aging Population

The global aging population is emerging as a significant driver behind the growth of the global acute pancreatitis market. As the world's demographic makeup shifts towards an increasingly elderly population, there is a parallel rise in the prevalence of acute pancreatitis, a condition that often affects older individuals more severely. This demographic shift has far-reaching implications for healthcare systems, medical practitioners, and the market for acute pancreatitis-related services.

Aging is often accompanied by physiological changes that can make individuals more susceptible to acute pancreatitis. The gradual decline in pancreatic function that comes with age, coupled with an increased likelihood of comorbid conditions such as gallstones and diabetes, contributes to a higher risk of developing acute pancreatitis among the elderly. This demographic segment is also more prone to complications from the condition, making early diagnosis and effective treatment essential.

The demand for healthcare services, including diagnostic procedures, treatment options, and post-acute care, has surged in response to the aging population's greater vulnerability to acute pancreatitis. Hospitals and healthcare facilities are witnessing an increased caseload of elderly patients seeking treatment for this condition, thereby driving the growth of the acute pancreatitis market.

Additionally, elderly individuals often require more specialized and comprehensive care, given their higher risk of developing severe forms of acute pancreatitis and experiencing complications. This necessitates additional healthcare resources, including medical personnel, specialized equipment, and rehabilitation services, all of which contribute to the market's expansion.

Furthermore, as healthcare providers adapt to the unique needs of an aging population, there is an emphasis on preventive measures and early intervention. Healthcare initiatives aimed at educating older individuals about the risk factors for acute pancreatitis and promoting healthier lifestyles can help mitigate the impact of this condition. These preventive efforts also contribute to the market by reducing the number of new cases and the severity of acute pancreatitis in elderly patients.

Key Market Challenges

High Treatment Costs

One of the primary drivers of high treatment costs for acute pancreatitis is the need for hospitalization. Severe cases of acute pancreatitis often require extended stays in the hospital, where patients receive specialized care, including pain management, nutritional support, and monitoring for complications. These extended hospital stays can result in exorbitant medical bills, particularly in countries with private healthcare systems.

Early and accurate diagnosis of acute pancreatitis is critical for effective management. However, diagnostic tests, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and blood work, can be expensive. The cost of these diagnostic procedures can escalate the overall financial burden on patients and healthcare systems.

In cases of severe acute pancreatitis, surgical interventions may be necessary to address complications like infected pancreatic necrosis or pseudocysts. Surgery, especially when performed laparoscopically or using minimally invasive techniques, can be costly and contribute significantly to the overall treatment expenses.

Patients with acute pancreatitis often require a combination of medications for pain relief, anti-inflammatory purposes, and antibiotics to manage infections. Additionally, nutritional support, including enteral or parenteral nutrition, may be necessary, adding to the treatment costs.

After the acute phase of the condition, some patients require long-term care and rehabilitation to regain their strength and functionality. These ongoing expenses can be substantial, particularly for patients who experience complications and require extended recovery periods. High treatment costs can exacerbate existing economic disparities in healthcare access. Patients with limited financial resources may delay seeking medical attention or forego necessary treatments due to financial concerns, which can lead to poorer outcomes.

Complexity of Diagnosis

Patients may experience abdominal pain, nausea, vomiting, and fever, which can overlap with symptoms of various other gastrointestinal and abdominal conditions. This ambiguity often leads to delayed or misdiagnosis, which can be detrimental to patient health.

Acute pancreatitis can vary widely in terms of severity, ranging from mild and self-limiting to severe with life-threatening complications. Determining the severity of the condition is crucial for guiding treatment decisions. However, accurately assessing the severity of acute pancreatitis can be challenging and misjudging it may result in inadequate or excessive interventions.

Healthcare professionals must distinguish acute pancreatitis from other conditions that present with similar symptoms, such as gallbladder disease, peptic ulcers, and gastritis. The overlap in symptoms and clinical presentations complicates the diagnostic process, often requiring multiple tests and evaluations.

While imaging studies like computed tomography (CT) scans and magnetic resonance imaging (MRI) are valuable tools for diagnosing acute pancreatitis, interpreting these images accurately can be complex. Radiological findings must be carefully assessed to identify signs of inflammation, pancreatic necrosis, or other complications, which may require specialized expertise.

Blood tests play a crucial role in diagnosing acute pancreatitis, as they can reveal elevated levels of pancreatic enzymes such as amylase and lipase. However, these enzyme levels can also be elevated in other conditions, leading to potential confusion in diagnosis and necessitating further evaluation.

Key Market Trends

Advancements in Minimally Invasive Surgery

Advancements in minimally invasive surgical techniques have emerged as a pivotal trend in the global acute pancreatitis market, revolutionizing the treatment landscape for this severe pancreatic condition. Minimally invasive surgery (MIS), which includes procedures like laparoscopy and endoscopy, offers significant benefits such as reduced postoperative pain, shorter hospital stays, and faster patient recovery times. These advantages have not only improved patient outcomes but also contributed to the growth of the acute pancreatitis market in several ways.

One of the primary ways in which MIS is boosting the market is by enhancing patient comfort and overall satisfaction. Traditional open surgeries for acute pancreatitis often involve larger incisions and more extensive tissue disruption, leading to prolonged postoperative pain and recovery periods. In contrast, minimally invasive approaches involve smaller incisions, resulting in less pain, reduced scarring, and shorter hospitalization. This patient-centric focus has made MIS an attractive option for both patients and healthcare providers, driving its adoption and contributing to market growth.

Moreover, the faster recovery times associated with MIS enable patients to return to their daily activities and work sooner, minimizing the economic burden of extended hospital stays and rehabilitation. This not only improves patients' quality of life but also reduces the overall healthcare costs associated with acute pancreatitis management, making it a cost-effective choice for healthcare systems.

In addition to its patient-centric advantages, MIS has also expanded the pool of eligible candidates for surgical intervention in acute pancreatitis cases. Traditional open surgery may not be suitable for patients with certain comorbidities or those in a critical condition due to the invasive nature of the procedure. However, minimally invasive techniques are often more accessible and can be adapted for a broader range of patients, ensuring that more individuals receive timely surgical treatment when needed.

Innovations in Drug Therapies

Innovations in drug therapies are playing a pivotal role in boosting the global acute pancreatitis market, offering new hope and more effective treatment options for individuals suffering from this severe pancreatic condition. Acute pancreatitis, characterized by inflammation of the pancreas, can lead to excruciating pain and life-threatening complications. Recent developments in pharmaceutical research and the introduction of novel drug therapies have brought about several key advancements in the management of acute pancreatitis.

One of the primary ways in which innovations in drug therapies are contributing to market growth is by addressing the inflammation associated with acute pancreatitis. Inflammation is a key driver of tissue damage and complications in this condition. Promising drug candidates, such as protease inhibitors and anti-inflammatory agents, have demonstrated the potential to reduce the severity of inflammation, limiting tissue damage and improving patient outcomes. By targeting the underlying inflammatory processes, these drugs offer a more targeted and effective approach to managing acute pancreatitis.

Pain management is another critical aspect of acute pancreatitis treatment, and pharmaceutical advancements have led to more efficient and tailored pain relief options. Pain control is essential for patients' comfort and to facilitate their recovery. Innovations in this area include the development of analgesics and pain management protocols that are both effective and less likely to cause adverse side effects, thereby enhancing the overall patient experience.

Moreover, innovations in drug therapies are focused on preventing complications associated with acute pancreatitis, such as infections and organ failure. By introducing medications that target these specific complications, pharmaceutical companies are contributing to a more comprehensive approach to acute pancreatitis management. These innovations are expected to reduce the morbidity and mortality associated with the condition, further driving the demand for these drug therapies within the market.

Segmental Insights

Treatment Insights

Based on the Treatment, Nutritional Support emerged as the dominant segment in the global market for Global Acute Pancreatitis Market in 2022 . Adequate nutrition is essential for the healing process, as it supports tissue repair and reduces the risk of complications. Malnourished patients with acute pancreatitis are at a higher risk of infection and delayed recovery. Malnutrition can exacerbate the severity of acute pancreatitis and increase the likelihood of developing complications, such as infected pancreatic necrosis. Providing nutritional support helps reduce these risks.

Nutritional support can also aid in pain management. It can help reduce pancreatic stimulation, as oral intake of food triggers pancreatic enzyme secretion. By providing nutrition through alternative routes, such as enteral or parenteral feeding, patients can experience reduced pain associated with oral intake.

Diagnosis Insights

Based on the Diagnosis, the Retail Pharmacy segment emerged as the dominant player in the global market for Global Acute Pancreatitis Market in 2022. Imaging tests, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and ultrasound, provide visual confirmation of pancreatic inflammation and any associated complications. These tests offer a direct view of the pancreas, allowing healthcare professionals to assess the extent of inflammation, presence of necrosis, and other abnormalities.

Imaging tests are instrumental in achieving a rapid diagnosis of acute pancreatitis. They provide immediate visual evidence of the condition, which is particularly important in severe cases where early intervention is crucial. Prompt diagnosis enables healthcare providers to initiate treatment promptly, improving patient outcomes.

Regional Insights

North America emerged as the dominant player in the global Acute Pancreatitis Market in 2022, holding the largest market share. North America boasts a highly advanced and well-developed healthcare infrastructure. The region is home to world-class hospitals, clinics, and medical facilities, equipped with state-of-the-art diagnostic and treatment technologies. This infrastructure is pivotal in providing efficient and effective care for acute pancreatitis patients. North America has a vast pool of healthcare professionals with specialized expertise in treating acute pancreatitis. Gastroenterologists, pancreatologists, surgeons, and other specialists are readily available to diagnose and manage the condition, ensuring that patients receive high-quality care..

Key Market Players

• SCM Lifescience

• GNT Pharma Co

• Baxter International Inc.

• B. Braun Melsungen AG

• General Electric Company

• Medtronic Plc

• Boston Scientific Corporation

• Fresenius Kabi USA

• McNeil Consumer Healthcare

• Sun BioPharma

Report Scope:

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Acute Pancreatitis Market, By Treatment:

• Intravenous Fluid
• Nutritional Support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Other treatments

Global Acute Pancreatitis Market, By Diagnosis:

• Imaging tests
• Laboratory Tests

Global Acute Pancreatitis Market, By End-User:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Global Acute Pancreatitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Acute Pancreatitis Market.

Available Customizations:

• Global Acute Pancreatitis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Acute Pancreatitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments)
  • 4.2.2. By Diagnosis (Imaging tests, Laboratory Tests)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Diagnosis
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Acute Pancreatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Diagnosis
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Acute Pancreatitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Diagnosis
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Acute Pancreatitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Diagnosis
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Acute Pancreatitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Diagnosis
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Acute Pancreatitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Diagnosis
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Acute Pancreatitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Diagnosis
      • 5.3.5.2.3. By End-User

6. Europe Acute Pancreatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Acute Pancreatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Acute Pancreatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Acute Pancreatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Acute Pancreatitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Diagnosis
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Acute Pancreatitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Diagnosis
      • 6.3.5.2.3. By End-User

7. North America Acute Pancreatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Acute Pancreatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Acute Pancreatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Acute Pancreatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End-User

8. South America Acute Pancreatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Acute Pancreatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Acute Pancreatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Acute Pancreatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Acute Pancreatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Acute Pancreatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Acute Pancreatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Acute Pancreatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Acute Pancreatitis Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Acute Pancreatitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. SCM Lifescience
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. GNT Pharma Co
• 14.3. Baxter International Inc.
• 14.4. B. Braun Melsungen AG
• 14.5. General Electric Company
• 14.6. Medtronic Plc
• 14.7. Boston Scientific Corporation
• 14.8. Fresenius Kabi USA
• 14.9. McNeil Consumer Healthcare
• 14.10. Sun BioPharma

15. Strategic Recommendations

16. About Us & Disclaimer